NASDAQ:BBIO BridgeBio Pharma Q4 2024 Earnings Report $72.38 -0.06 (-0.08%) Closing price 04:00 PM EasternExtended Trading$72.91 +0.53 (+0.73%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast BridgeBio Pharma EPS ResultsActual EPS-$1.31Consensus EPS -$1.09Beat/MissMissed by -$0.22One Year Ago EPSN/ABridgeBio Pharma Revenue ResultsActual Revenue$5.88 millionExpected Revenue$4.04 millionBeat/MissBeat by +$1.84 millionYoY Revenue GrowthN/ABridgeBio Pharma Announcement DetailsQuarterQ4 2024Date2/20/2025TimeBefore Market OpensConference Call DateThursday, February 20, 2025Conference Call Time12:30PM ETUpcoming EarningsBridgeBio Pharma's Q3 2026 earnings is estimated for Wednesday, October 28, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) BridgeBio Pharma Earnings HeadlinesBridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeptember 10, 2026 | seekingalpha.comBridgeBio Pharma: Attruby Peak Sales Set To RiseSeptember 10, 2026 | seekingalpha.comHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fraction of the cost? That's the core advantage options offer traders at every level. The Beginner's Guide to Options breaks down leverage, income strategies, and real trade examples in plain English — including a little-known approach many traders use to reduce costs and improve profit potential. Download your free copy before this offer expires.September 14 at 1:00 AM | Base Camp Trading (Ad)BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeptember 9, 2026 | seekingalpha.comBridgeBio Pharma, Inc.: Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 TrialSeptember 9, 2026 | finanznachrichten.deBridgeBio's Oral Infigratinib Shows Benefits Beyond Growth Achondroplasia Phase 3 PROPEL 3 TrialSeptember 9, 2026 | rttnews.comSee More BridgeBio Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BridgeBio Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BridgeBio Pharma and other key companies, straight to your email. Email Address About BridgeBio PharmaBridgeBio Pharma (NASDAQ:BBIO) is a biopharmaceutical company focused on discovering, developing and delivering medicines for patients with genetically driven diseases and cancers. Founded in 2015, the company operates through a group of subsidiary biotechnology businesses, each generally focused on a specific disease area or therapeutic program. BridgeBio’s research and development activities span rare diseases, genetically defined cancers, cardiovascular conditions and other serious disorders. Its portfolio includes therapies designed to address the underlying biological causes of disease, including small-molecule medicines and other targeted treatments. The company’s subsidiary Eidos Therapeutics developed acoramidis, marketed in the United States as Attruby, which received U.S. Food and Drug Administration approval for adults with cardiomyopathy caused by transthyretin-mediated amyloidosis. BridgeBio supports research, clinical development and commercialization activities through its subsidiaries and collaborators, with clinical programs and business operations serving patients and healthcare markets in the United States and other international geographies. The company is led by founder and Chief Executive Officer Neil Kumar, who has overseen its strategy of building and advancing multiple precision-medicine companies.View BridgeBio Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Kings to Buy While They’re Still Beaten DownAnalysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed EarningsMarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundThe End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
